Global leader in advanced cardiac monitoring and defibrillation products selects clinivation’s Regulatory Services Solution to support its international market clearance operations.
Natick, MA, June 4, 2008 – clinivation, Inc. announced today that Cardiac Science Corporation [NASDAQ: CSCX] has selected clinivation’s Regulatory solution.
“Cardiac Science is working to become a worldwide provider of cardiology-related products,” remarked Joseph Kozikowski, M.D., clinivation’s President and Chief Executive Officer. “We are pleased that Cardiac Science’s senior management has selected clinivation to help accelerate their critical regulatory research process,” he continued.
Clinivation’s Regulatory Practice delivers expertise, experience, and an outstanding track record.
About Cardiac Science Corporation
Cardiac Science is a global leader in the development, manufacture and marketing of diagnostic and therapeutic cardiology products and services. Formed by the merger of Cardiac Science, Inc. and Quinton Cardiology Systems in September 2005, the predecessor companies have a rich legacy of technology development in the cardiology device market.
Cardiac Science Corporation provides a full spectrum of cardiology products and services that help protect hearts and save lives. From devices designed to identify the early stages of heart disease-such as Electrocardiographs, Cardiac Stress Testing Systems, and Holter Monitors-to sophisticated systems that enable Cardiac Rehabilitation and Cardiology Data Management-to innovative and patented defibrillators including Automated External Defibrillators (AEDs) that provide assistance to victims of sudden cardiac arrest for both medical and public markets.
